Clinical Pharmacy Services Publications

Title

Intrathecal topotecan in adult patients with neoplastic meningitis

UMMS Affiliation

Department of Pharmacy

Date

10-24-2006

Document Type

Article

Medical Subject Headings

Antineoplastic Agents; Drug Toxicity; Female; Humans; *Injections, Spinal; Male; Medical Audit; Meningeal Neoplasms; Middle Aged; Retrospective Studies; Topotecan; Treatment Outcome

Disciplines

Pharmacy and Pharmaceutical Sciences

Abstract

PURPOSE: The efficacy and safety of intrathecal topotecan were assessed in patients with neoplastic meningitis (NM) by retrospective chart review.

SUMMARY: Fourteen patients (median age, 57 years) with NM were treated with the standard of care (i.e., regional or systemic chemotherapy or irradiation or both) plus intrathecal topotecan between January 2004 and September 2005. Three patients developed NM in the setting of systemic cancer; 11 patients had primary central nervous system (CNS) malignancies. All patients received 0.4 mg of topotecan intrathecally two times per week. The efficacy of intrathecal topotecan was assessed on the basis of the number of doses to cerebrospinal fluid (CSF) cytologic clearing--defined as the disappearance of malignant cells from a previously positive CSF cytology. Safety was evaluated by chart documentation of adverse events that might have been associated with topotecan given intrathecally. Of the 11 patients with primary CNS tumors, 6 patients achieved CSF clearing after the first dose of intrathecal topotecan, 2 patients after the second dose, and 1 patient after the fifth dose. For the 3 patients with secondary CSF tumors, 1 patient achieved CSF clearing after the third dose and 2 patients did not reach the primary endpoint. Overall, 6 of the 14 patients achieved CSF clearing after the first dose of intrathecal topotecan; in 10 of the 14 patients, CSF clearing of malignant cells was observed at some point during treatment. Toxicity was modest. The most common adverse effect reported was fatigue.

CONCLUSION: Intrathecal topotecan appeared to be effective and safe in adult patients with NM.

Rights and Permissions

Citation: Am J Health Syst Pharm. 2006 Nov 1;63(21):2083-6. Link to article on publisher's site

Related Resources

Link to Article in PubMed